Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Thomas E LewRory BennettVictor S LinAshley WhitechurchSasanka Mithila HandunnettiPaula MarltonYandong ShenStephen P MulliganJoshua CasanPiers BlomberyConstantine S TamAndrew W RobertsJohn Francis SeymourPhillip A ThompsonMary A AndersonPublished in: Blood advances (2024)